B lymphocytes as effector cells in the immunotherapy of cancer | Zendy

Namm Jukes P. | Zendy; Li Qiao | Zendy; Lao Xiangming | Zendy; Lubman David M. | Zendy; He Jintang | Zendy; Liu Yashu | Zendy; Zhu Jianhui | Zendy; Wei Shuang | Zendy; Chang Alfred E. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

B lymphocytes as effector cells in the immunotherapy of cancer

Author(s) -

Namm Jukes P.,

Li Qiao,

Lao Xiangming,

Lubman David M.,

He Jintang,

Liu Yashu,

Zhu Jianhui,

Wei Shuang,

Chang Alfred E.

Publication year - 2011

Publication title -

journal of surgical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.201

H-Index - 111

eISSN - 1096-9098

pISSN - 0022-4790

DOI - 10.1002/jso.22093

Subject(s) - effector , medicine , immune system , malignancy , immunotherapy , antigen , immunology , cancer immunotherapy , cancer , antibody , cancer research , pathology

Over the years, the role of B cells in the host immune response to malignancy has been overshadowed by our focus on T cells. Nevertheless, B cells play important roles as antigen‐presenting cells and in the production of antibodies. Furthermore, B cells can function as effector cells that mediate tumor destruction on their own. This review will highlight the various functions of B cells that are involved in the host response to tumor. J. Surg. Oncol. 2012;105:431–435. © 2011 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research